Transcatheter Mitral Valve Market Report 2025

The transcatheter mitral valve market size has grown strongly in recent years. It will grow from $1.47 billion in 2024 to $1.61 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to the increasing adoption of minimally invasive cardiac procedures, higher clinical trial success rates for early transcatheter mitral valve replacement (TMVR) devices, expansion of hospital infrastructure in developed regions, rising prevalence of rheumatic heart disease in low-income countries, and the growth of specialized training programs for interventional cardiologists.

The transcatheter mitral valve market size is expected to see strong growth in the next few years. It will grow to $2.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to rising demand for catheter-based treatment options among younger patients, an expanding pipeline of next-generation transcatheter mitral valve replacement (TMVR) devices, increased focus on early diagnosis using AI-based imaging, a growing number of regulatory approvals for TMV devices, and the adoption of real-time navigation and imaging technologies in transcatheter mitral valve procedures. Major trends in the forecast period include advancements in AI-powered imaging for valve assessment, development of advanced material coatings to enhance biocompatibility, creation of personalized TMV solutions through 3D printing, innovations in delivery catheter flexibility and precision, and integration of digital twin technology for procedural planning.

The rising prevalence of heart diseases is expected to drive the growth of the transcatheter mitral valve market in the coming years. Heart diseases are conditions that impair the structure or function of the heart, reducing its efficiency in pumping blood. This increasing prevalence is largely fueled by aging populations, as age-related deterioration of the heart and blood vessels heightens susceptibility to conditions such as mitral valve regurgitation, heart failure, and arrhythmias. Transcatheter mitral valves treat heart disease by repairing or replacing damaged mitral valves, restoring healthy blood flow between the heart’s chambers, improving cardiac function, and alleviating symptoms. For example, according to the Centers for Disease Control and Prevention in October 2024, coronary heart disease was the most common type of heart disease in 2022, causing 371,506 deaths. Each year, roughly 805,000 people in the United States experience a heart attack, with first-time occurrences (605,000) happening about three times more often than recurrent cases (200,000). As a result, the growing prevalence of heart diseases is propelling the expansion of the transcatheter mitral valve market.

Key players in the transcatheter mitral valve market are concentrating on developing advanced devices, such as transcatheter mitral valve replacement (TMVR) systems, to broaden treatment options for high-risk or inoperable patients. TMVR systems are minimally invasive devices that replace a damaged or diseased mitral valve with an artificial valve via a catheter-based approach, eliminating the need for open-heart surgery. For instance, in May 2025, Abbott Laboratories, a US-based medical device company, launched Tendyne, which received FDA approval. This self-expanding, nitinol-framed valve is available in multiple sizes to suit different anatomies and can be fully repositioned or retrieved during implantation. Delivered through a small chest incision, the system allows for a minimally invasive procedure typically completed in around 1.5 hours. Designed for quicker recovery, most patients can be discharged within three days, providing a transformative option for high-risk mitral valve patients without viable surgical alternatives.

In April 2024, TechWald Holding S.p.A., an Italy-based medical technology investment company, acquired Valcare Medical Inc. for an undisclosed sum. This acquisition aims to strengthen TechWald Holding’s presence in the structural heart device market, focusing on transcatheter mitral valve repair and replacement. The deal enhances its cardiovascular portfolio, accelerates Valcare’s device development and commercialization, and bolsters its position in minimally invasive heart valve therapies. Valcare Medical Inc., based in Israel, specializes in minimally invasive transcatheter treatments for mitral regurgitation.

Major players in the transcatheter mitral valve market are Abbott Laboratories, Medtronic Inc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Meril Life Sciences Private Limited, MicroPort Scientific Corporation, Venus Medtech Inc., Cardiac Dimensions Inc., JenaValve Technology Inc., Ancora Heart Inc, Peijia Medical Limited, Micro Interventional Devices Inc., 4C Medical Technologies Inc., NeoChord Inc., Xeltis AG, Valcare Medical Inc., Colibri Heart Valve LLC, MitrAssist Ltd., HighLife SAS, Navigate Cardiac Structures Inc., Cardiovalve Ltd.

North America was the largest region in the transcatheter mitral valve market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transcatheter mitral valve market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the transcatheter mitral valve market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

A transcatheter mitral valve is a minimally invasive device designed to repair or replace a damaged mitral valve without requiring open-heart surgery. It is delivered to the heart via a thin catheter inserted through a vein or artery, improving blood flow and alleviating symptoms associated with mitral valve disease. This approach is particularly beneficial for patients at high risk for traditional surgical procedures.

The primary product types of transcatheter mitral valves include transcatheter mitral valve replacement and transcatheter mitral valve repair. Transcatheter mitral valve replacement involves inserting a new artificial or biological mitral valve into the heart using a catheter, usually through a blood vessel. It is indicated for conditions such as mitral stenosis and mitral regurgitation and is utilized by various end users, including hospitals, ambulatory surgical centers, and cardiac catheterization laboratories.

The transcatheter mitral valve market research report is one of a series of new reports that provides transcatheter mitral valve market statistics, including transcatheter mitral valve industry global market size, regional shares, competitors with a transcatheter mitral valve market share, detailed transcatheter mitral valve market segments, market trends and opportunities, and any further data you may need to thrive in the transcatheter mitral valve industry. The transcatheter mitral valve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The transcatheter mitral valve market consists of sales of transcatheter annuloplasty devices, guiding catheters, chordal repair devices, and adjunctive imaging and navigation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.